Cure My Disease

Don't miss your cure!

 Log in / Sign up

BREAST CANCER BREAKTHROUGH: NEW STUDY TESTS SKIPPING CHEMO FOR TARGETED PILL

NCT ID NCT06953882

Recruiting now Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen May 27, 2026 · Last updated Jun 08, 2026 · Updated 2 times

Summary

This study is for people with a common type of breast cancer (ER-positive, HER2-negative) that has a moderate to high risk of coming back based on tumor size and lymph node involvement, but a low genetic risk score. The goal is to see if patients can safely skip chemotherapy and instead take a combination of a targeted drug (ribociclib) and hormone therapy for one year. About 140 participants will choose their treatment path, and researchers will track how many stop the drug early due to side effects or other reasons.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Yale University

    RECRUITING

    New Haven, Connecticut, 06511, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HER2-NEGATIVE BREAST CANCER

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.

ER-POSITIVE, HER2-NEGATIVE BREAST CANCER